Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLVS
  • CUSIP: 18946410
Key Metrics:
  • Previous Close: $57.90
  • 50 Day Moving Average: $59.50
  • 200 Day Moving Average: $38.89
  • 52-Week Range: $38,585,000.00 - $11.57
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.93
  • P/E Growth: -0.38
  • Market Cap: $2.23B
  • Outstanding Shares: 38,585,000
  • Beta: 1.97
  • Return on Equity: -178.58%
  • Return on Assets: -56.45%
  • Debt-to-Equity Ratio: 4.92%
  • Current Ratio: 5.61%
  • Quick Ratio: 5.61%
Additional Links:
Companies Related to Clovis Oncology:

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $61.92 (6.94% upside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetDetails
2/23/2017J P Morgan Chase & CoSet Price TargetHold$58.00View Rating Details
2/23/2017Morgan StanleyBoost Price TargetOverweight$68.00 -> $72.00View Rating Details
2/23/2017Credit Suisse GroupBoost Price TargetOutperform$53.00 -> $70.00View Rating Details
2/3/2017Chardan CapitalDowngradeNeutral -> Sell$36.00View Rating Details
1/27/2017Bank of America CorpInitiated CoverageBuy$74.00View Rating Details
1/26/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$77.00View Rating Details
1/23/2017Stifel NicolausBoost Price TargetBuy$52.00 -> $86.00View Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00View Rating Details
12/20/2016Janney Montgomery ScottSet Price TargetHold$38.00View Rating Details
9/23/2016SunTrust Banks, Inc.Boost Price TargetBuy$38.00 -> $50.00View Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00View Rating Details
3/28/2016Leerink SwannBoost Price TargetOutperform$104.00 -> $110.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$23.00 -> $19.00View Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.44)($3.12)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($1.99)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.82)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.30)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.07)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.96)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
Current Year EPS Consensus Estimate: $-5.25 EPS
Next Year EPS Consensus Estimate: $-2.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($2.04)($2.04)($2.04)
Q4 20161($1.94)($1.94)($1.94)
Q1 20171($1.53)($1.53)($1.53)
Q2 20171($1.54)($1.54)($1.54)
Q3 20171($1.54)($1.54)($1.54)
Q4 20171($1.35)($1.35)($1.35)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 88.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logoClovis Oncology : Two Clovis shareholders accuse cancer drug maker of violating FDA rules (NASDAQ:CLVS) - February 25 at 4:09 PM
News IconClovis Oncology Inc (CLVS) Releases Earnings Results, Misses Expectations By $-0.16 EPS (NASDAQ:CLVS) - February 24 at 12:23 PM logoCLOVIS ONCOLOGY, INC. Files SEC form 10-K, Annual Report (NASDAQ:CLVS) - February 23 at 9:20 PM
News IconClovis Oncology, Inc. (CLVS) Given New $72.00 Price Target at Morgan Stanley (NASDAQ:CLVS) - February 23 at 4:19 PM
News IconFred Alger Management Inc. Acquires 50508 Shares of Clovis Oncology, Inc. (CLVS) (NASDAQ:CLVS) - February 23 at 4:19 PM logoCommit To Purchase Clovis Oncology At $35, Earn 12.3% Using Options (NASDAQ:CLVS) - February 23 at 4:19 PM logoJ.P. Morgan Boosts Price Target for Clovis Oncology Inc (CLVS) on Back of Additional Pipeline Value (NASDAQ:CLVS) - February 23 at 4:19 PM logoClovis Oncology 4Q Loss Misses Street (CLVS) (NASDAQ:CLVS) - February 23 at 4:19 PM logoEdited Transcript of CLVS earnings conference call or presentation 22-Feb-17 9:30pm GMT (NASDAQ:CLVS) - February 23 at 4:19 PM logoClovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca (NASDAQ:CLVS) - February 23 at 4:19 PM logoClovis Oncology 4Q Loss Below Street Estimates (NASDAQ:CLVS) - February 23 at 4:19 PM
News IconClovis Oncology Inc (CLVS) Releases Earnings Results, Misses Expectations By $-0.16 EPS - Highland Mirror (NASDAQ:CLVS) - February 23 at 2:33 AM logoClovis Oncology : reports 4Q loss (NASDAQ:CLVS) - February 22 at 9:32 PM logoClovis reports 4Q loss (NASDAQ:CLVS) - February 22 at 9:32 PM
News IconA Keen Look At The Chart For Clovis Oncology, Inc. (CLVS) - NY Stock News (NASDAQ:CLVS) - February 22 at 4:30 PM
News IconStock Buzz on Clovis Oncology, Inc. (NASDAQ:CLVS): Can They Meet the Earnings Target of $-1.65 - Winfield Review (NASDAQ:CLVS) - February 22 at 4:30 PM
News IconWhy to Keeping Eye on Clovis Oncology, Inc. (CLVS), Apollo Global Management, LLC (APO)? - StockNewsJournal (NASDAQ:CLVS) - February 22 at 4:30 PM logoClovis Oncology Announces 2016 Operating Results (NASDAQ:CLVS) - February 22 at 4:30 PM logoCLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:CLVS) - February 22 at 4:30 PM logoClovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CLVS) - February 22 at 4:30 PM
News IconHow Does the Chart Look for Clovis Oncology, Inc. (CLVS) ? - The USA Commerce (NASDAQ:CLVS) - February 20 at 4:07 PM
News IconClovis Oncology Inc (NASDAQ:CLVS): Our Members Made 60% Quick Money After Buying at $41 In Just 8-Week (NASDAQ:CLVS) - February 19 at 4:04 PM logoNoteworthy Friday Option Activity: SAGE, BAX, CLVS (NASDAQ:CLVS) - February 18 at 10:39 AM
News IconInvestor Guide: Taking a Look at Indicators for Clovis Oncology Inc. (CLVS) - Midway Monitor (NASDAQ:CLVS) - February 16 at 10:58 AM
News IconWhat are Analyst's Indicators for Treehouse Foods, Inc. (THS ... - The USA Commerce (NASDAQ:CLVS) - February 14 at 5:08 PM
News IconClovis Oncology, Inc. (NASDAQ:CLVS) Long-Term Growth Estimate At $29.42 - Transcript Daily (NASDAQ:CLVS) - February 14 at 5:08 PM logoUpdate in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS) announced by Shareholders Foundation (NASDAQ:CLVS) - February 14 at 5:08 PM
News IconClovis Oncology, Inc. (NASDAQ:CLVS) Stock ABR At 2.25 - Stock Observer (NASDAQ:CLVS) - February 12 at 9:25 PM
News IconPrice Target Of Clovis Oncology, Inc. (NASDAQ:CLVS)At $63.714 - Transcript Daily (NASDAQ:CLVS) - February 12 at 9:25 PM
News IconAnalytical Guide for Kohl's Corporation (KSS), Clovis Oncology, Inc. (CLVS) Stakeholders - The USA Commerce (NASDAQ:CLVS) - February 10 at 2:45 AM
News IconChardan Capital Downgrades Clovis Oncology Inc to Sell with Price Target $36 (NASDAQ:CLVS) - February 9 at 9:44 PM logoClovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22 (NASDAQ:CLVS) - February 9 at 9:44 PM logoBiotech Tesaro Climbs on Takeout Reports (NASDAQ:CLVS) - February 8 at 4:40 PM
News IconTechnical Levels in Review for Clovis Oncology Inc. (CLVS) - Davidson Register (NASDAQ:CLVS) - February 7 at 5:28 PM
News IconThe Case for and Against Clovis Oncology, Inc. (CLVS) - StockNewsJournal (NASDAQ:CLVS) - February 7 at 5:28 PM
News IconWhat is Recommendation from Analysts on Clovis Oncology Inc (NASDAQ:CLVS)? - Post Registrar (NASDAQ:CLVS) - February 6 at 4:24 PM
News IconClovis Oncology Inc (CLVS) is Downgraded by Chardan Capital ... - Highland Mirror (NASDAQ:CLVS) - February 3 at 9:39 PM logoStock's Trend Analysis Report: Nordstrom, Inc. (JWN), Clovis ... - iStreetWire (NASDAQ:CLVS) - February 2 at 4:40 PM
News IconThe Technical Case for and Against Clovis Oncology, Inc. (CLVS) - The USA Commerce (NASDAQ:CLVS) - February 2 at 4:40 PM logoClovis Oncology (CLVS), Strata Oncology Enter Pact to Accelerate Enrollment in Rucaparib Prostate Cancer ... - (NASDAQ:CLVS) - February 2 at 4:40 PM logoClovis Oncology (CLVS), Strata Oncology Enter Pact to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program (NASDAQ:CLVS) - February 1 at 4:38 PM logoClovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program (NASDAQ:CLVS) - February 1 at 4:38 PM logo8:33 am Clovis Oncology and Strate Oncology announce an agreement to accelerate patient identification and enrollment for Clovis' ongoing TRITON clinical trial program (NASDAQ:CLVS) - February 1 at 4:38 PM
News IconTechnicals in Focus for Clovis Oncology, (CLVS) - The USA Commerce (NASDAQ:CLVS) - February 1 at 2:51 AM logoClovis Oncology Inc (CLVS)'s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN ... - Insider Monkey (blog) (NASDAQ:CLVS) - February 1 at 2:51 AM
News IconHow Analysts Feel About Clovis Oncology Inc (CLVS) After Reaching 52-Week High? (NASDAQ:CLVS) - January 31 at 4:47 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Clovis Oncology Inc. (CLVS) - Springdale Times (NASDAQ:CLVS) - January 30 at 6:52 AM
News IconClovis Oncology, Inc. (NASDAQ:CLVS) (NASDAQ:CLVS) - January 29 at 2:36 AM
News IconPiperJaffray Upgrades the shares of Clovis Oncology, Inc. (NASDAQ:CLVS) to Overweight (NASDAQ:CLVS) - January 29 at 2:36 AM
News IconTom Brady Sr. calls NFL's handling of Deflategate a witch hunt (NASDAQ:CLVS) - January 28 at 3:50 AM


What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

12 brokerages have issued 12 month price objectives for Clovis Oncology's stock. Their forecasts range from $23.00 to $110.00. On average, they anticipate Clovis Oncology's share price to reach $61.92 in the next twelve months.

When will Clovis Oncology announce their earnings?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern." (2/8/2017)

  • Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
  • J P Morgan Chase & Co analysts commented, "CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating." (8/9/2016)

  • Piper Jaffray Companies analysts commented, "We are assuming coverage of Clovis Oncology with a Neutral rating and an $18 PT ($28 prior) as we do not have enough confidence ahead of a key binary event (rociletinib ODAC/ PDUFA) to justify a more constructive outlook at this time. With the updated rociletinib efficacy data falling short of AstraZeneca’s Tagrisso, we struggle to see a clear regulatory and commercial path forward and are remaining on the sidelines. Behind rociletinib, the company’s PARP inhibitor, rucaparib, has demonstrated early signs of clinical benefit, but again runs into an AZN drug already approved with a similar mechanism (Lynparza), and we are not convinced that rucaparib has demonstrated clear differentiation in what looks like a small and crowded market. In sum, CLVS is a player in the attractive area of targeted oncology therapy and we view CLVS’ risk/reward profile at current levels as sufficiently balanced given the uncertainty with rociletinib and competitive landscape with rucaparib. • Rociletinib path uncertain: The deterioration in objective response rate (ORR) last fall (~60% to 32% at the 625 mg dose) casts doubt on the approvability and commercial opportunity in the absence of a meaningful point of differentiation with AstraZeneca’s Tagrisso, which has been FDA approved and rapidly incorporated into NCCN guidelines for treatment of T790M+ patients with NSCLC. Even if CLVS is able to convince ODAC next week and the FDA that the appropriate comparator is chemotherapy given the accelerated approval of Tagrisso, we struggle to see a meaningful commercial opportunity in T790M positive patients. That said, the opportunity for rociletinib in T790M negative patients may ultimately prove attractive; rociletinib has shown a confirmed ORR of 29% in this patient population (n = 24). In addition, combination studies with checkpoint inhibitors are commencing. • Rucaparib active, but in a crowded field: CLVS is currently completing a rolling NDA submission (expected in Q2) for PARP inhibitor rucaparib in ovarian cancer patients who have received 3 or more lines of therapy, and approval may occur by YE. Rucaparib has demonstrated activity in both early lines of therapy as well as heavily pre-treated patients, though with small numbers, patient selection / heterogeneity combined with a highly competitive landscape, rucaparib’s profile is not differentiated yet, in our view. CLVS is advancing rucaparib in patients with "BRCA-like" tumor signatures as well as prostate cancer and beyond, and we await further details on the profile in these patients. • What could change? Although we remain Neutral on the shares given the NT uncertainty with rociletinib and crowded PARP field, Clovis’ cash reserves (~$528M YE15), organization and CEO with a long term track record of creating value keep us watching closely for opportunities to become constructive. RISKS TO ACHIEVEMENT OF PRICE TARGET Rociletinib and rucaparib may fail/succeed in its trials or fail to/gain regulatory approval COMPANY DESCRIPTION Clovis is a drug developer for oncology pursuing three small-molecule candidates. Page 1 of 79 Clovis Oncology, Inc. Piper Jaffray does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decisions. This report should be read in conjunction with important disclosure information, including an attestation under Regulation Analyst certification, found on pages 78 – 79 of this report or at the following site: 2 of 79 Clovis Oncology, Inc.Page 3 of 79 Clovis Oncology, Inc.Page 4 of 79 Clovis Oncology, Inc.•" (4/5/2016)

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (9.86%), Patrick Lee, MD (9.86%), Integrated Core Strategies (US) LLC (5.10%), State Street Corp (5.55%), Boxer Capital LLC (2.20%) and Franklin Resources Inc. (1.47%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and M James Barrett.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, FMR LLC, Marshall Wace LLP, Frontier Wealth Management LLC, Columbia Wanger Asset Management LLC and Clough Capital Partners L P.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Perceptive Advisors LLC, Renaissance Technologies LLC, Royce & Associates LP, Guggenheim Capital LLC, Fred Alger Management Inc., Franklin Resources Inc. and Artal Group S.A..

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Clovis Oncology stock cost?

One share of Clovis Oncology stock can currently be purchased for approximately $57.90.

Clovis Oncology (NASDAQ:CLVS) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Earnings History Chart

Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)

Dividend History Chart

Dividend Payments by Quarter for Clovis Oncology (NASDAQ:CLVS)

Last Updated on 2/27/2017 by Staff